

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

Pieter Sonneveld, MD¹; Meletios A. Dimopoulos, MD²; Meral Beksac, MD³; Bronno van der Holt, PhD⁴; Sara Aquino, MD⁵; Heinz Ludwig, MD⁶; Sonja Zweegman, MD⁷; Thilo Zander, MD⁸; Elena Zamagni, MD⁹; Ruth Wester, MD¹; Roman Hajek, MD¹⁰; Lucia Pantani, MD¹¹; Luca Dozza, MSc¹²; Francesca Gay, MD¹³; AnneMaria Cafro, MD¹⁴; Luca De Rosa, MD¹⁵; Annamaria Morelli, MD¹⁶; Henrik Gregersen, MD¹⁷; Nina Gulbrandsen, MD¹⁸; Petra Cornelisse, MSc¹⁹; Rosella Troia, PharmD¹³; Stefania Oliva, MD¹³; Vincent van de Velden, PhD²⁰; KaLung Wu, MD²¹; Paula F. Ypma, MD²²; Gerard Bos, MD²³; Mark-David Levin, MD²⁴; Luca Pour, PhD²⁵; Christoph Driessen, MD²⁶; Annemiek Broijl, MD¹; Alexandra Croockewit, MD²⁷; Monique C. Minnema, MD²⁸; Anders Waage, MD²⁹; Cecilie Hveding, MD³⁰; Niels W. C. J. van de Donk, MD⁷; Massimo Offidani, MD³¹; Giuseppe A. Palumbo, MD³²; Andrew Spencer, MD³³; Mario Boccadoro, MD¹³; and Michele Cavo, MD³⁴

abstract

PURPOSE To address the role of consolidation treatment for newly diagnosed, transplant eligible patients with multiple myeloma in a controlled clinical trial.

PATIENTS AND METHODS The EMN02/HOVON95 trial compared consolidation treatment with two cycles of bortezomib, lenalidomide, and dexamethasone (VRD) or no consolidation after induction and intensification therapy, followed by continuous lenalidomide maintenance. Primary study end point was progression-free survival (PFS).

RESULTS Eight hundred seventy-eight eligible patients were randomly assigned to receive VRD consolidation (451 patients) or no consolidation (427 patients). At a median follow-up of 74.8 months, median PFS with adjustment for pretreatment was prolonged in patients randomly assigned to VRD consolidation (59.3 v 42.9 months, hazard ratio [HR] = 0.81; 95% CI, 0.68 to 0.96; $P = .016$). The PFS benefit was observed across most predefined subgroups, including revised International Staging System (ISS) stage, cytogenetics, and prior treatment. Revised ISS3 stage (HR, 2.00; 95% CI, 1.41 to 2.86) and ampl1q (HR, 1.67; 95% CI, 1.37 to 2.04) were significant adverse prognostic factors. The median duration of maintenance was 33 months (interquartile range 13-86 months). Response \geq complete response (CR) after consolidation versus no consolidation before start of maintenance was 34% versus 18%, respectively ($P < .001$). Response \geq CR on protocol including maintenance was 59% with consolidation and 46% without ($P < .001$). Minimal residual disease analysis by flow cytometry in a subgroup of 226 patients with CR or stringent complete response or very good partial response before start of maintenance demonstrated a 74% minimal residual disease–negativity rate in VRD-treated patients. Toxicity from VRD was acceptable and manageable.

CONCLUSION Consolidation treatment with VRD followed by lenalidomide maintenance improves PFS and depth of response in newly diagnosed patients with multiple myeloma as compared to maintenance alone.

J Clin Oncol 39:3613-3622. © 2021 by American Society of Clinical Oncology

BACKGROUND AND MOTIVATION

The role of consolidation treatment for newly diagnosed, transplant-eligible patients with multiple myeloma (TE-NDMM) needs prospective evaluation.

INTRODUCTION

The treatment outcome of patients with multiple myeloma (MM) significantly improved by the introduction of proteasome inhibitors and immunomodulatory agents, resulting in higher response rates, as well as longer progression-free survival (PFS) and overall survival (OS).

High-dose melphalan followed by autologous stem-cell transplantation (HDM/ASCT) remains a backbone.¹ Maintenance with lenalidomide is now a standard treatment.² We reported the results of the EMN02/HO95

trial, which demonstrates the superiority for PFS of HDM/ASCT over chemotherapy.³ Few trials prospectively addressed the effect of consolidation treatment in NDMM.⁴ Superior complete response (CR) or near-complete response rates and PFS were demonstrated with bortezomib, thalidomide, and dexamethasone (VTD) versus thalidomide-dexamethasone as consolidation after double ASCT for NDMM.⁵ The BMT CTN0702 (STaMINA) trial compared a second ASCT with consolidation plus maintenance or maintenance alone.⁶ At a follow-up of 38 months, no difference was observed. A later analysis demonstrated a PFS advantage of double ASCT in high-risk disease.⁷ One retrospective analysis demonstrated an advantage for VTD consolidation.⁸ Recent prospective trials usually included standard consolidation.⁹⁻¹¹ In the EMN02/HO95

ASSOCIATED CONTENT

Appendix Protocol

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on August 17, 2021 and published at ascopubs.org/journal/jco on September 14, 2021; DOI <https://doi.org/10.1200/JCO.21.01045>

CONTEXT

Key Objective

The role of consolidation treatment in multiple myeloma (MM) has not been conclusively established. In the EMN02/HOVON95 trial, the relevance of consolidation therapy using bortezomib, lenalidomide, and dexamethasone (VRD) followed by lenalidomide maintenance compared with maintenance alone in transplant-eligible newly diagnosed patients with MM was prospectively evaluated.

Knowledge Generated

The results show that consolidation plus maintenance after either bortezomib, melphalan, and prednisone or high-dose melphalan, autologous stem-cell transplantation deepens the response and significantly improves the progression-free survival (PFS) in comparison with maintenance alone. In patients achieving minimal residual disease negativity, the PFS was superior to those not achieving such state.

Relevance (S. Lentzsch)

Consolidation with VRD followed by lenalidomide maintenance improves PFS and overall response rate in transplant-eligible and lenalidomide-naïve newly diagnosed patients with MM compared with maintenance alone. By contrast, in the STAMINA trial (BMT CTN 0702), VRD consolidation did not improve PFS. The data suggest a significant benefit of lenalidomide, bortezomib, and dexamethasone consolidation in lenalidomide-naïve patients.*

*Relevance section written by JCO Associate Editor Suzanne Lentzsch, MD, PhD.

trial, patients were randomly assigned to consolidation treatment with two cycles of bortezomib, lenalidomide, and dexamethasone (VRD) versus no consolidation, followed by lenalidomide maintenance until progressive disease or toxicity.

PATIENTS AND METHODS

Study Design

This randomized, open-label, phase III study was performed by the European Myeloma Network (EMN).³ Previously untreated patients age 18-65 years with symptomatic MM stage 1-3 according to the International Staging System (ISS), measurable disease defined by the presence of serum M-protein > 10 g/L or urine M-protein > 200 mg/24 hours or abnormal free light-chain ratio with involved free light-chain > 100 mg/L or proven plasmacytoma by biopsy, and a WHO performance status grade 0-2 or 3 when because of myeloma were included (Appendix Table A1, online only). Exclusion criteria were listed in the recent publication of Part 1 and in the Protocol (online only). All patients provided written informed consent. The study was approved by independent ethics committees or the institutional review board of participating sites and performed according to the International Conference on Harmonization Guidelines on Good Clinical Practice and the principles of the Declaration of Helsinki. The Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) sponsored and designed this study.

Treatment and Procedures

After registration patients received induction with 3-4 cycles of vincristine, cyclophosphamide, and dexamethasone and

mobilization of stem cells was performed.³ Next, patients were randomly assigned (R1) to receive four cycles of bortezomib, melphalan, and prednisone (VMP) or HDM/ASCT once or twice as described.³ Within 2 months after ASCT or last VMP, a second random assignment (R2) assigned eligible patients to two 28-day cycles of VRD consolidation VRD (bortezomib [1.3 mg/m² either intravenous or subcutaneously once daily on days 1, 4, 8, and 11] combined with lenalidomide [25 mg orally once daily, days 1-21] and dexamethasone [20 mg orally once daily, on days 1, 2, 4, 5, 8, 9, 11, and 12]) or no consolidation. No masking or stratification was done. Patients started lenalidomide maintenance (10 mg orally once daily on days 1-21 of a 28-day cycle) 1-2 months after ASCT or consolidation until disease progression (PD) or toxicity.

Outcomes

The primary end point PFS was defined as time from R2 to disease progression or death. Secondary end points were partial response or higher defined by the International Uniform Response Criteria for Multiple Myeloma¹² (Appendix Table A3, online only), OS from R2 until death from any cause, and toxicity. Predefined high-risk prognostic subgroups for PFS included cytogenetic abnormalities defined by fluorescent in situ hybridization: deletion (17p) in ≥ 20% of enriched plasma cells; t(4;14) in ≥ 10% of enriched plasma cells; t(14;16) in ≥ 10% of enriched plasma cells; and amplification 1q. Standard clinical variables such as hemoglobin content, serum creatinine, and serum lactate dehydrogenase were included.¹³

Disease assessment was performed before and after consolidation and every 2 months until progression according to standard criteria (Appendix Table A3). Minimal residual disease (MRD) assessment was performed by

multicolor flow cytometry in bone marrow with a detection of 10^{-4} to 10^{-5} in central laboratories of the EMN Network using a standard protocol.^{14,15} Here, we report the final analysis, which was performed in November 2020 at a median follow-up of 74.8 months from R2.

Statistical Analysis

The sample size was estimated based on the primary end point PFS from R2. Assuming a median PFS of 25 months without consolidation and 32 months with consolidation, we estimated that with uniform accrual for 30 months and additional follow-up of 24 months after the last patient was randomly assigned, 848 patients were required to be randomly assigned 1:1 and 514 events of PD or death would be needed to provide 80% power to detect a 22% reduced risk of PD or death (hazard ratio [HR] 0.78) in the consolidation group compared with no consolidation, using Cox regression analysis, with an overall two-sided significance level of 0.05. Two prespecified interim analyses were performed in 2016 and 2018 after 33% and 66% of events had occurred; therefore, the *P* value for the primary end point at the final analysis was set at .045. These interim analyses showed PFS was longer with consolidation than without consolidation. An independent data monitoring committee reviewed the results of interim analyses. Efficacy was analyzed in the intention-to-treat population, which includes all eligible patients in R2 who also were in R1. PFS and OS were estimated by Kaplan-Meier method from the date of R2. Cox regression analysis including only the R2 arm and the stratification factor R1 group (VMP v HDM) was used for the primary comparison of PFS between treatment groups and to estimate HRs and 95% CIs. The consistency of effects of consolidation versus no consolidation within predefined subgroups was evaluated using interaction-*p* terms between each of the covariates included in the Cox model. Forest plots were generated to illustrate PFS from R2 within subgroups.

As a post hoc analysis, we also performed a multivariable Cox regression analysis with R2 arm together with the variables that were statistically significant in the multivariable analysis for PFS in the VMP versus HDM random assignment.³ To include all patients in this analysis, the method of multiple imputation by chained equations was used to cope with possible missing data on these covariates. Responses were compared between treatments using the chi-squared test. Safety was assessed in all patients who received at least one dose of study drugs. Toxicities were tabulated as adverse events (CTCAE version 4) and second primary malignancies (SPMs). Cumulative incidence curves of SPMs were generated by treatment group. MRD was evaluated in patients with at least one evaluable MRD sample. The prognostic impact of MRD on PFS from R2 was assessed by comparing PFS from R2 in MRD-negative versus MRD-positive patients. Patients with the last sample during or after intensification with VMP or HDM/ASCT but before start of VRD or start of maintenance,

whichever first, were considered MRD-negative if the last sample was MRD-negative. All other patients, including those without an evaluable MRD sample, were considered as MRD-positive at R2. Similarly, the prognostic impact of MRD on PFS from start of maintenance was assessed. In that analysis, patients were considered MRD-negative if the last sample during or after intensification, VRD consolidation, or within 4 months after start maintenance was MRD-negative. All analyses were performed using Stata (version 15.1). Data were monitored by an external contract organization and verified for accuracy by a supporting research team at the EMN data center. This trial is registered with the EU Clinical Trials Register (EudraCT 2009-017903-28) and ClinicalTrials.gov identifier: [NCT01208766](https://clinicaltrials.gov/ct2/show/study/NCT01208766).

Role of Funding Sources

Funding for this study was provided by the Dutch National Cancer Society and by Janssen and Celgene. The study was performed as an independent, investigator-sponsored study. All patients provided written informed consent and the study was approved by the independent ethics committee or institutional review board of each participating hospital. Funders had no role in study design, data collection, data analysis, data interpretation, or manuscript writing. The corresponding author had full access to the data and carried the final responsibility for the submission of the manuscript.

RESULTS

Consolidation

From February 2011 to April 2014, a total of 1,503 patients age ≤ 65 years with MM were enrolled in 172 EMN centers, of whom 1,500 were eligible. 1,197 patients were randomly assigned (stratified by ISS stage) to VMP (495 patients) or HDM (one or two ASCT; 702 patients). The results were recently published and an update on OS was presented.^{3,16} For the second random assignment, 878 patients were eligible and 24 patients were ineligible (Appendix [Table A1](#)). Patients were randomly assigned to consolidation (arm B, 451 patients) or no consolidation (arm A, 427 patients; Appendix [Fig A1](#), online only). Median follow-up from R2 of 630 patients still alive was 74.8 months (interquartile range [IQR] 64.4-82.3 months). Response status at R2 was equal in both arms, ie, \geq CR (18%, 22%), \geq very good partial response (67%, 67%), and \geq PR (91%, 93%) according to uniform criteria (ST3). At the time of analysis, 519 events for PFS after R2 had been reported. The median PFS from R2 was 59.3 (95% CI, 49.8 to 66.9) versus 42.9 (95% CI, 39.3 to 50.5) months, respectively (HR 0.81 in favor of consolidation, 95% CI, 0.68 to 0.96; *P* = .016; [Fig 1](#)). Five-year PFS from R2 was 50% (95% CI, 45 to 54) with consolidation and 41% (95% CI, 37 to 46) without consolidation. The primary comparison of PFS from R2 between treatment groups also included the R1 group (VMP v HDM), and showed that prior treatment with HDM/ASCT (HR, 0.77;




FIG 1. PFS from R2 with consolidation plus maintenance versus maintenance alone. HR, hazard ratio; P/D, progression or death; PFS, progression-free survival; VRD, bortezomib, lenalidomide, and dexamethasone.

95% CI, 0.64 to 0.92; $P = .003$) was statistically significant. There was no significant interaction between the first random assignment (R1) and the arms of the R2 random assignment, indicating that the benefit of consolidation is not different between VMP and HDM (Fig 2).

Consolidation reduced the risk of progression or death in most predefined subgroups, including revised ISS stage I-III, standard-risk cytogenetics, and prior treatment arms (Fig 3). However, the interaction term for del(17p) was significant ($P = .04$), indicating that VRD consolidation was beneficial in patients without del(17p), HR = 0.77 (95% CI, 0.64 to 0.94), but not in del(17p), HR = 1.50 (95% CI, 0.84 to 2.67).

Univariate Cox regression analysis of all patients randomly assigned in R2 showed that revised ISS stage 3 (HR, 2.00; 95% CI, 1.41 to 2.86), B2M > 5.5, ISS stage 3, t(4;14), revised ISS 2 versus 1, high-risk cytogenetics (HR, 1.49; 95% CI, 1.20 to 1.85), and addition of chromosome 1q by fluorescent in situ hybridization (HR, 1.67; 95% CI, 1.37 to 2.04) at diagnosis were adverse prognostic factors for PFS from R2.

The multiple imputation by chained equation method was used to cope with missing data in the multivariable analysis because platelet count was missing in 2%, revised ISS in 15%, and cytogenetics in 20% of patients. The post hoc multivariable Cox regression analysis with R2 arm together

with the variables that were statistically significant in the multivariable analysis for PFS in the R1 (VMP v HDM) random assignment revealed that all covariates were statistically significant, except for standard-risk cytogenetics ($P = .08$). The significant covariates as displayed in Table 1 also show that the HRs for VRD consolidation (R2; 0.81 v 0.81) and HDM (R1; 0.79 v 0.77) are almost identical to those in the primary analysis of PFS2.¹⁶

Before R2, response \geq CR was 22% (95% CI, 18 to 26) versus 18% (95% CI, 15 to 22) of patients. Response \geq CR before start of maintenance was 34% (95% CI, 29 to 38) versus 18% (95% CI, 15 to 22) after consolidation or no consolidation, respectively ($P < .001$). Response \geq CR on protocol was 59% (95% CI, 54 to 63) with consolidation and 46% (95% CI, 41 to 51) without ($P < .001$; Table 2).

Maintenance

Maintenance with lenalidomide 10 mg was initiated in 847 patients, 428 (95%) with and 419 (98%) without consolidation. The median duration of maintenance was not different at 35.7 months (IQR 13-78 months) and 31.8 months (IQR 14-88 months), respectively ($P = .24$; Appendix Fig A2, online only). At 5 years after random assignment, 35% (consolidation) and 30% (no consolidation) of patients were still receiving maintenance treatment. Maintenance was discontinued in 288 of 428 (67%) versus 302 of 419 (72%) patients, of whom 186 of 288 (65%) versus 189 of 302 (63%) because of




FIG 2. Effect of consolidation treatment on PFS from R2 in patients who were randomly assigned in (A) R1 according to VMP, (B) single or double ASCT, (C) single ASCT, or (D) double ASCT. ASCT, autologous stem-cell transplantation; HR, hazard ratio; P/D, progression or death; PFS, progression-free survival; VMP, bortezomib, melphalan, and prednisone; VRD, bortezomib, lenalidomide, and dexamethasone.

progressive disease after consolidation or no consolidation, respectively.

At a median follow-up of 73.4 months, median PFS from start of maintenance was 57.5 months in the consolidation arm and 42.3 months without consolidation (HR = 0.83; 95% CI, 0.70 to 0.99; $P = .04$).

At 4 years after R2, OS was 81%-82% in both arms, whereas at 6 years, OS was 76% (95% CI, 71 to 79) with consolidation and 69% (95% CI, 64 to 73) without consolidation, indicating that longer follow-up is required to evaluate OS (Appendix Fig A3, online only).

Toxicity

Ninety-six percent of patients randomly assigned to consolidation completed two cycles of VRD. Toxicity was acceptable and manageable with 28% CTCAE grade 3 or 4, mainly neutropenia (13%), thrombocytopenia (12%), and infections (5%; Appendix Table A2, online only). The

cumulative incidence of SPM excluding superficial skin cancer at 6 years was 5% and 6%, respectively.

MRD

Minimal residual disease studies were initiated only when a standard assessment protocol became available. MRD was performed by 8-color flow cytometry on bone marrow aspirates of patients in CR or stringent complete response or very good partial response at R2 and at the start of maintenance. Of 878 randomly assigned patients in the consolidation ITT analysis, 103 patients had an MRD sample after the last treatment before R2. Thirty-five of 49 (71%) patients without consolidation were MRD-negative, versus 44 of 54 (81%) with consolidation. Similarly, 226 patients had at least one MRD sample before or within 4 months after start maintenance, which were considered as MRD sample at the start of maintenance. Sixty-two of 89 (70%) of evaluable patients without consolidation were MRD-negative, versus 101 of 137 (74%) with




FIG 3. Forest plot for PFS from R2 of predefined subgroups. HDM, high-dose melphalan; HR, hazard ratio; ISS, International Staging System; PFS, progression-free survival; PR, partial response; sCR, stringent complete response; VGPR, very good partial response; VMP, bortezomib, melphalan, and prednisone; VRD, bortezomib, lenalidomide, and dexamethasone.

consolidation. Figure 4 shows the Kaplan-Meier curves of PFS from R2 random assignment according to R2 arm and MRD status at R2 and PFS from start maintenance according to R2 arm and MRD status at start maintenance. Both figures indicate that PFS is improved in MRD-negative patients. Median PFS from start of maintenance in patients randomly assigned to no consolidation was 85.3 months in MRD-negative patients and 39.3 months in MRD-positive patients (HR = 0.49; 95% CI, 0.32 to 0.73; $P < .001$), and

in patients randomly assigned to consolidation, it was median 70.1 months in MRD-negative patients and 50.6 months in MRD-positive patients (HR = 0.65; 95% CI, 0.47 to 0.89; $P = .008$). The detailed analysis of MRD for the EMN02/HO95 trial including R1 is described elsewhere.¹⁴

DISCUSSION

This randomized trial evaluated the efficacy of consolidation after intensification with VMP or HDM/ASCT in TE-NDMM. Standard treatment for TE-NDMM consists of 3-6 cycles of induction therapy followed by melphalan 200 mg/m² and ASCT.¹⁷ Lenalidomide maintenance is now used for continuous or fixed duration (1-2 years). Consolidation therapy is given to improve the response after ASCT and to prevent early relapse.¹⁸ However, there are few published randomized consolidation studies.

The use of consolidation therapy with VTD compared with thalidomide-dexamethasone was associated with a significant upgrade of overall response and CR rate, resulting in enhanced PFS.^{5,19} The phase III PETHEMA/GEM2012 study demonstrated that consolidation with VRD in all patients after ASCT improves CR and MRD-negativity.²⁰ Other trials used VRD as consolidation.^{10,21} In the

TABLE 1. Multivariate Analysis for Progression-Free Survival

Covariates	HR	95% CI	P
R2: VRD consolidation v none	0.81	0.68 to 0.96	.015
R1: HDM v VMP	0.79	0.66 to 0.94	.009
≥ VGPR at the time of R2 random assignment	0.70	0.59 to 0.84	< .001
R-ISS I v II ^a	0.77	0.63 to 0.95	.015
R-ISS I v III ^a	0.52	0.37 to 0.73	< .001
Platelet count ≥ 150 × 10 ⁹ /L ^a	0.60	0.47 to 0.77	< .001

Abbreviations: HDM, high-dose melphalan; HR, hazard ratio; ISS, International Staging System; R-ISS, revised International Staging System; VGPR, very good partial response; VMP, bortezomib, melphalan, and prednisone; VRD, bortezomib, lenalidomide, and dexamethasone.

^aR-ISS and platelet count measured at entry in the trial.

TABLE 2. Response Status

Time	Response % of Patients	Consolidation No	Consolidation Yes	P
Before R2	≥ CR	18	22	.15
	≥ VGPR	67	67	.94
	ORR	91	93	.38
Before maintenance	≥ CR	18	34	< .001
	≥ VGPR	67	78	< .001
Best on protocol	≥ CR	46	59	< .001
	≥ VGPR	87	89	.26

Abbreviations: CR, complete response; ORR, overall response rate; VGPR, very good partial response.

STaMINA trial, four cycles of VRD consolidation did not improve PFS when compared with a second HDM/ASCT or no consolidation.⁶ Double HDM/ASCT was superior in the high-risk group at the longer follow-up.⁷ Possible explanations for the different outcome of consolidation are the heterogeneous induction regimens and 5%-32% noncompliance rate in STaMINA, whereas in EMN02, all patients were lenalidomide-naïve and randomly assigned after prior ASCT or VMP just before consolidation. Together, these trials may be informative for OS after additional follow-up.

Several trials in TE-NDMM used standard consolidation.^{1,22} It was part of the Cassiopeia trial comparing daratumumab-VTD versus VTD and in the Griffin trial using daratumumab-lenalidomide, bortezomib, and dexamethasone versus lenalidomide, bortezomib, and dexamethasone.^{9,11} It is unknown to what extent consolidation has contributed to the outcome of these trials. A superior PFS after consolidation was only demonstrated in the current EMN02/HO95 trial. The impact on OS requires still longer follow-up. This

uncertainty illustrates the need for exploratory predictive end points such as MRD assessment after induction, after transplant, and during subsequent treatment.^{12,23-25} We observed a deepening of response after consolidation including ≥ CR rate from 22% to 34% and sCR from 6% to 12%, resulting in a ≥ CR rate on protocol of 59% compared with 46% without consolidation. The MRD-negativity rate did not significantly differ between patients with or without consolidation. The imbalance in MRD-negativity at R2 prevents any formal conclusion about MRD response achieved with consolidation before start of maintenance. The relevance of this finding pertains to the observation that MRD-negative patients had a significantly longer PFS. Overall, consolidation resulted in a consistent improvement of median PFS after R2 from 43 to 59 months.

These data indicate that consolidation improves PFS across subgroups, except in the small subgroup of high-risk (del17p) patients. The results also show that continuous maintenance with lenalidomide is feasible. Like in previous trials and in a meta-analysis, a significant PFS benefit was observed.^{2,26-28} A higher probability of achieving CR or sCR after start of maintenance was observed, especially after consolidation. This benefit was also observed in recent trials in transplant-eligible patients where CD38 antibody therapy was followed by maintenance.^{2,9,11,29} The Spanish group observed an upgrade of MRD-negativity by 17% during prolonged maintenance with lenalidomide and ixazomib.²⁴ Hence, the question remains: Which duration of maintenance is optimal.³⁰

In the current trial, there is a trend that consolidation improves OS. However, while the OS curves separate after 5-6 years, median OS was not reached at 84 months in both arms. Consequently, longer follow-up is needed to evaluate the full-scale impact of consolidation followed by




FIG 4. (A) PFS from R2 by R2-arm and MRD status and (B) PFS from start of maintenance by R2-arm and MRD status before start maintenance. MRD, minimal residual disease; P/D, progression or death; PFS, progression-free survival; VRD, bortezomib, lenalidomide, and dexamethasone.

continuous maintenance. Future trials will evaluate to what extent consolidation treatment will improve treatment outcome when quadruplet induction therapy with a CD38 antibody may become standard.

In conclusion, consolidation treatment with VRD followed by continuous lenalidomide maintenance improves PFS and quality of response in NDMM as compared to maintenance alone. The rate of toxicity and SPMs is acceptable.

AFFILIATIONS

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

²Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

³Department of Hematology, Ankara University School of Medicine, Ankara, Turkey

⁴Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

⁵IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

⁶Wilhelminen Cancer Research Institute, c/o Wilhelminenspital, Vienna, Austria

⁷Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

⁸Medical Oncology, Luzerner Kantonshospital, Luzern, Switzerland

⁹IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli" and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy

¹⁰University Hospital Ostrava, Ostrava, Czech Republic

¹¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy

¹²Department of Experimental, Diagnostic and Experimental Medicine, Seràgnoli Institute of Hematology, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy

¹³Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy

¹⁴ASST Grande Ospedale Metropolitano, Niguarda, Milan, Italy

¹⁵Ospedale San Camillo Forlanini, Rome, Italy

¹⁶Department of Hematology, Transfusion Medicine and Biotechnology Santo Spirito, Civic Hospital, Pescara, Italy

¹⁷Department of Haematology, Aalborg University Hospital, Aalborg, Denmark

¹⁸Department of Hematology, Oslo University Hospital, Oslo, Norway

¹⁹HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

²⁰Department of Immunology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

²¹Department of Hematology, ZNA Stuivenberg, Antwerp, Belgium

²²Department of Hematology, Haga Ziekenhuis, The Hague, the Netherlands

²³Maastricht University Medical Center, Maastricht, the Netherlands

²⁴Albert Schweitzer Ziekenhuis, Dordrecht, the Netherlands

²⁵University Hospital Brno, Brno, Czech Republic

²⁶Department of Oncology/Hematology, Kantonsspital, St Gallen, Switzerland

²⁷Department of Hematology, Radboud University Medical Centre, Nijmegen, the Netherlands

²⁸Department of Hematology, University Medical Centre Utrecht, the Netherlands

²⁹Department of Hematology, St Olav Hospital, Trondheim, Norway

³⁰Sahlgrenska University Hospital, Gothenburg, Sweden

³¹Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy

³²Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia," University of Catania, Catania, Italy

³³Department of Haematology, Alfred Hospital-Monash University, Melbourne, Australia

³⁴IRCCS S.Orsola-Malpighi, Istituto di Ematologia "Seràgnoli,"

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi di Bologna, Bologna, Italy

CORRESPONDING AUTHOR

Pieter Sonneveld, MD, Department of Hematology, Erasmus MC Cancer Institute, PO Box 2040, 3000CA Rotterdam, the Netherlands; e-mail: p.sonneveld@erasmusmc.nl.

PRIOR PRESENTATION

Presented in part at the European Hematology Association 24th Annual Meeting, Amsterdam, the Netherlands, June 14-17, 2018; the virtual American Society of Hematology 62nd Annual Meeting and Exposition, December 5-8, 2020, San Diego, CA.

SUPPORT

Supported by the Dutch Cancer Society (grant 2010-4798), by the European Myeloma Network, and by unrestricted grants from Celgene and Janssen.

CLINICAL TRIAL INFORMATION

NCT01208766

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.21.01045>.

AUTHOR CONTRIBUTIONS

Conception and design: Pieter Sonneveld, Meletios A. Dimopoulos, Meral Beksac, Bronno van der Holt, Heinz Ludwig, Elena Zamagni, Petra Cornelisse, KaLung Wu, Christoph Driessen, Anders Waage, Michele Cavo

Administrative support: Pieter Sonneveld, Bronno van der Holt, Petra Cornelisse, Rosella Troia, Luca Pour

Provision of study materials or patients: Pieter Sonneveld, Meletios A. Dimopoulos, Meral Beksac, Heinz Ludwig, Sonja Zweegman, Annamaria Morelli, Paula F. Ypma, Gerard Bos, Luca Pour, Monique C. Minnema, Anders Waage, Cecilie Hveding, Massimo Offidani, Giuseppe A. Palumbo, Michele Cavo

Collection and assembly of data: Pieter Sonneveld, Meletios A. Dimopoulos, Meral Beksac, Heinz Ludwig, Sonja Zweegman, Thilo Zander, Elena Zamagni, Luca Dozza, AnneMaria Cafro, Luca De Rosa, Annamaria Morelli, Henrik Gregersen, Nina Gulbrandsen, Petra Cornelisse, Rosella Troia, Stefania Oliva, Vincent van de Velden, Luca Pour, Annemiek Broijl, Monique C. Minnema, Anders Waage, Cecilie Hveding, Niels W. C. J. van de Donk, Massimo Offidani, Giuseppe A. Palumbo, Andrew Spencer, Michele Cavo

Data analysis and interpretation: Pieter Sonneveld, Meletios A. Dimopoulos, Meral Beksac, Bronno van der Holt, Sara Aquino, Thilo Zander, Elena Zamagni, Ruth Wester, Roman Hajek, Lucia Pantani, Luca Dozza, Francesca Gay, Henrik Gregersen, Petra Cornelisse, KaLung Wu, Paula F. Ypma, Gerard Bos, Mark-David Levin, Christoph Driessen, Alexandra Croockewit, Monique C. Minnema, Anders Waage, Cecilie

Hveding, Niels W. C. J. van de Donk, Giuseppe A. Palumbo, Andrew Spencer, Mario Boccadoro, Michele Cavo

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

The authors thank the HOVON Data Center team and European Myeloma Network Data Center for their efforts. The authors also thank the members of the Data and Safety Monitoring Board J. Bladé, M. Delforge, and K. Wheatley.

Participating physicians are listed in [Appendix 1](#).

REFERENCES

- Cavo M, Rajkumar SV, Palumbo A, et al: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. *Blood* 117:6063-6073, 2011
- Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med* 366:1782-1791, 2012
- Cavo M, Gay F, Beksac M, et al: Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): A multicentre, randomised, open-label, phase 3 study. *Lancet Haematol* 7:e456-e468, 2020
- Krishnan A, Sonneveld P: Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma? *Lancet Haematol* 7:e445-e446, 2020
- Cavo M, Pantani L, Petrucci MT, et al: Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. *Blood* 120:9-19, 2012
- Stadtmauer EA, Pasquini MC, Blackwell B, et al: Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial. *J Clin Oncol* 37:589-597, 2019
- Hari P, Pasquini MC, Stadtmauer EA, et al: Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). *J Clin Oncol* 38, 2020 (suppl 15; abstr 8506)
- Leleu X, Fouquet G, Hebraud B, et al: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. *Leukemia* 27:2242-2244, 2013
- Moreau P, Attal M, Hulin C, et al: Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study. *Lancet* 394:29-38, 2019
- Attal M, Lauwers-Cances V, Hulin C, et al: Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. *N Engl J Med* 376:1311-1320, 2017
- Voorhees PM, Kaufman JL, Laubach J, et al: Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial. *Blood* 136:936-945, 2020
- Kumar S, Paiva B, Anderson KC, et al: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol* 17:e328-e346, 2016
- Sonneveld P, Avet-Loiseau H, Lonial S, et al: Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. *Blood* 127:2955-2962, 2016
- Oliva S, Bruinink DHO, Rihova L, et al: Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. *Blood Cancer J* 11:106, 2021
- Hofste op Bruinink D, Oliva S, Rihova L, et al: Standardization of flow cytometric minimal residual disease assessment in international clinical trials—A feasibility study from the European Myeloma Network. *Haematologica* 106:1496-1499, 2020
- Cavo M, Gay F, Beksac M, et al: Upfront autologous hematopoietic stem-cell transplantation improves overall survival in comparison with bortezomib-based intensification therapy in newly diagnosed multiple myeloma: Long-term follow-up analysis of the randomized phase 3 EMN02/HO95 study. *Blood* 136:37-38, 2020 (suppl 1)
- Dimopoulos MA, Moreau P, Terpos E, et al: Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. *Ann Oncol* 32:309-322, 2021
- Barlogie B, Haessler J, Pineda-Roman M, et al: Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: An important variable to be considered in clinical trial designs. *Cancer* 112:2720-2725, 2008
- Cavo M, Tacchetti P, Patriarca F, et al: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. *Lancet* 376:2075-2085, 2010
- Rosinol L, Oriol A, Rios R, et al: Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. *Blood* 134:1337-1345, 2019
- Durie BGM, Hoering A, Abidi MH, et al: Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. *Lancet* 389:519-527, 2017
- Attal M, Richardson PG, Moreau P: Drug combinations with transplantation for myeloma. *N Engl J Med* 377:93-94, 2017
- Munshi NC, Avet-Loiseau H, Anderson KC, et al: A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. *Blood Adv* 4:5988-5999, 2020
- Paiva B, Puig N, Cedena MT, et al: Measurable residual disease by next-generation flow cytometry in multiple myeloma. *J Clin Oncol* 38:784-792, 2020
- Costa LJ, Derman BA, Bal S, et al: International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. *Leukemia* 35:18-30, 2021
- McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplantation for multiple myeloma. *N Engl J Med* 366:1770-1781, 2012
- Palumbo A, Cavallo F, Gay F, et al: Autologous transplantation and maintenance therapy in multiple myeloma. *N Engl J Med* 371:895-905, 2014

28. McCarthy PL, Holstein SA, Petrucci MT, et al: Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis. *J Clin Oncol* 35:3279-3289, 2017
29. Goldschmidt H, Dimopoulos MA, Rajkumar SV, et al: Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. *Leukemia* 34:3019-3027, 2020
30. Goldschmidt H, Mai EK, Durig J, et al: Response-adapted lenalidomide maintenance in newly diagnosed myeloma: Results from the phase III GMMG-MM5 trial. *Leukemia* 34:1853-1865, 2020

ASCO Answers—The Ideal Take-Home Patient Education Resource



ASCO has created helpful resources to support your patients and their caregivers. **ASCO Answers** patient education materials provide trusted information on cancer types, diagnosis, treatment, side effects, and coping in three convenient formats: fact sheets, topic-specific booklets, and comprehensive, patient-friendly guides.

ASCO Answers can be purchased from the ASCO Store at **cancer.net/estore**. Free domestic shipping. Members save 20%.

Cancer.NetTM

Doctor-Approved Patient Information from **ASCO**®

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Pieter Sonneveld

Consulting or Advisory Role: Celgene, Janssen, Amgen, Karyopharm Therapeutics, CARsgen Therapeutics

Research Funding: Janssen, Amgen, Skyline Diagnostics

Meletios A. Dimopoulos

Honoraria: Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, Beigene

Consulting or Advisory Role: Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, Beigene

Meral Beksac

Consulting or Advisory Role: Amgen, Janssen, Sanofi, Oncopeptides, Takeda

Travel, Accommodations, Expenses: Amgen, Janssen, Takeda, Sanofi

Meral Beksac

Consulting or Advisory Role: Celgene, Janssen-Cilag, Amgen, Takeda, Sanofi Pasteur, Oncopeptides

Speakers' Bureau: Amgen, Celgene, Janssen-Cilag, Sanofi Pasteur

Heinz Ludwig

Consulting or Advisory Role: Amgen, Janssen-Cilag, Sanofi, Seattle Genetics

Speakers' Bureau: Celgene, Bristol Myers Squibb, Janssen-Cilag, Amgen, Takeda

Research Funding: Takeda, Amgen

Sonja Zweegman

Consulting or Advisory Role: Janssen-Cilag, Takeda, Celgene, Sanofi, Oncopeptides

Research Funding: Janssen-Cilag, Takeda, Celgene

Travel, Accommodations, Expenses: Janssen-Cilag, Takeda, Celgene

Elena Zamagni

Honoraria: Janssen-Cilag, Celgene, Amgen, Bristol Myers Squibb, Takeda, GlaxoSmithKline, Oncopeptides, Sanofi

Consulting or Advisory Role: Celgene, Janssen-Cilag, Amgen, Sanofi

Travel, Accommodations, Expenses: Janssen-Cilag, Celgene, Amgen

Ruth Wester

Honoraria: Sanofi

Roman Hajek

Consulting or Advisory Role: Takeda, Amgen, Celgene, AbbVie, BMS, PharmaMar, Janssen-Cilag, Novartis

Speakers' Bureau: Takeda, Amgen

Research Funding: Novartis, BMS, Amgen, Celgene, Takeda

Lucia Pantani

Honoraria: Celgene, Janssen, Takeda, Amgen

Francesca Gay

Honoraria: Amgen, Bristol Myers Squibb, Celgene, Takeda, AbbVie, Janssen, GlaxoSmithKline

Consulting or Advisory Role: AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Oncopeptides, Roche, Takeda, Janssen, Bluebird bio

Stefania Oliva

Honoraria: Amgen, Celgene/Bristol Myers Squibb, Janssen

Consulting or Advisory Role: Adaptive Biotechnologies, Janssen, Amgen, Takeda

Vincent van de Velden

Research Funding: BD Biosciences, Pfizer, Janssen, Novartis/Navigate, Agilent/DAKO

Patents, Royalties, Other Intellectual Property: Patent EuroFlow MRD antibody tubes. No financial relationship

KaLung Wu

Consulting or Advisory Role: Janssen Oncology

Gerard Bos

Employment: CiMaas

Leadership: CiMaas

Stock and Other Ownership Interests: CiMaas

Honoraria: CiMaas

Mark-David Levin

Honoraria: AbbVie, Celgene, Janssen, Takeda

Travel, Accommodations, Expenses: Takeda, Janssen

Annemiek Broijl

Honoraria: Amgen, Sanofi, Celgene, Bristol Myers Squibb/Celgene, Janssen

Travel, Accommodations, Expenses: Bristol Myers Squibb/Celgene

Monique Minnema

Consulting or Advisory Role: Janssen-Cilag, Alnylam, Gilead Sciences

Speakers' Bureau: Celgene/Bristol Myers Squibb

Travel, Accommodations, Expenses: Celgene

Anders Waage

Honoraria: Janssen Oncology

Speakers' Bureau: Janssen Oncology

Cecilie Blimark

Honoraria: Bristol Myers Squibb/Celgene, Janssen, Takeda, Amgen

Consulting or Advisory Role: Adaptive Biotechnologies, Janssen, GlaxoSmithKline

Niels W. C. J. van de Donk

Consulting or Advisory Role: Janssen, Celgene, Bristol Myers Squibb, Novartis, Amgen, Servier, Takeda, Bayer

Speakers' Bureau: Janssen Research & Development, Celgene, Amgen, Bristol Myers Squibb

Research Funding: Janssen, Celgene, Amgen, Novartis, Bristol Myers Squibb, Cellectis

Massimo Offidani

Honoraria: BMS, Janssen, Celgene

Consulting or Advisory Role: Janssen

Giuseppe A. Palumbo

Consulting or Advisory Role: Novartis, Janssen Oncology, AOP Orphan Pharmaceuticals, AbbVie, AstraZeneca, Celgene/Bristol Myers Squibb

Speakers' Bureau: Novartis, Celgene/Bristol Myers Squibb, AbbVie

Travel, Accommodations, Expenses: Takeda, Novartis

Andrew Spencer

Honoraria: Janssen-Cilag, BMS

Consulting or Advisory Role: Janssen-Cilag, BMS

Speakers' Bureau: Janssen-Cilag

Research Funding: Janssen-Cilag

Mario Boccardo

Honoraria: Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, AbbVie

Consulting or Advisory Role: Janssen, GlaxoSmithKline

Research Funding: Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, Mundipharma

Michele Cavo

Honoraria: Janssen, Bristol Myers Squibb, Celgene, Sanofi, GlaxoSmithKline, Takeda, Amgen, Oncopeptides, AbbVie, Karyopharm Therapeutics, Adaptive Biotechnologies

Consulting or Advisory Role: Janssen, Bristol Myers Squibb, Celgene, Sanofi, GlaxoSmithKline, Takeda, Amgen, Oncopeptides, AbbVie, Karyopharm Therapeutics, Adaptive Biotechnologies

Speakers' Bureau: Janssen, Celgene

No other potential conflicts of interest were reported.

APPENDIX 1. PARTICIPATING PHYSICIANS

P. Mollee, Brisbane, Australia	P. P. Fattori, Meldola, Italy
E. Lee, Canberra, Australia	C. Musolino, Messina, Italy
A. Spencer, Melbourne, Australia	R. Bassan, Mestre, Italy
J. Taper, Sydney, Australia	A. M. Cafro, Milano, Italy
S. Machherndl-Spandl, Linz, Austria	P. Corradini, Milano, Italy
R. Greil, Salzburg, Austria	G. Torelli, Modena, Italy
H. Ludwig, Vienna, Austria	F. Ferrara, Napoli, Italy
K. Beel, Antwerp, Belgium	L. Catalano, Napoli, Italy
K. L. Wu, Antwerp, Belgium	A. Gabbas, Nuoro, Italy
V. Delrieu, Haine-Saint-Paul, Belgium	G. Semenzato, Padova, Italy
B. Hodossy, Liege, Belgium	S. Siragusa, Palermo, Italy
C. Dopchie, Tournai, Belgium	A. Corso, Pavia, Italy
I. Vrelust, Turnhout, Belgium	S. Ballanti, Perugia, Italy
L. Pour, Brno, Czech Republic	G. Visani, Pesaro, Italy
V. Maisnar, Hradec Kralove, Czech Republic	F. Fioritoni, Pescara, Italy
V. Scudla, Olomouc, Czech Republic	C. Cellini, Ravenna, Italy
R. Hajek, Ostrava, Czech Republic	F. Nobile, Reggio Calabria, Italy
A. Jungová, Plzen, Czech Republic	B. Gamberi, Reggio Emilia, Italy
J. Straub, Prague, Czech Republic	P. Tosi, Rimini, Italy
H. Gregersen, Aalborg, Denmark	P. Musto, Rionero in Vulture, Italy
N. F. Andersen, Aarhus C, Denmark	G. Avisati, Roma, Italy
P. Gimsing, Copenhagen, Denmark	L. Annino, Roma, Italy
C. Helleberg, Herlev, Denmark	P. De Fabritis, Roma, Italy
N. Abildgaard, Odense, Denmark	R. Foà, Roma, Italy
U. Frølund, Roskilde, Denmark	F. Pisani, Roma, Italy
M. A. Dimopoulos, Athens, Greece	L. De Rosa, Roma, Italy
H. Steingrimsdóttir, Reykjavik, Iceland	G. La Verde, Roma, Italy
A. Levis, Alessandria, Italy	A. Santoro, Rozzano, Italy
M. Offidani, Ancona, Italy	A. Gozzetti, Siena, Italy
P. Galieni, Ascoli Piceno, Italy	A. M. Liberati, Terni, Italy
N. Cantore, Avellino, Italy	F. Gay, Torino, Italy
G. Specchia, Bari, Italy	U. Vitolo, Torino, Italy
A. Rambaldi, Bergamo, Italy	V. Pavone, Tricase, Italy
M. Cavo, Bologna, Italy	G. Palladini, Trieste, Italy
N. Pescosta, Bolzano, Italy	F. Patriarca, Udine, Italy
G. Rossi, Brescia, Italy	L. Plawny, Luxembourg, Luxembourg
G. Quarta, Brindisi, Italy	M. Westerman, Alkmaar, the Netherlands
L. N. Giorgio, Cagliari, Italy	J. C. Regelink, Amersfoort, the Netherlands
M. Aglietta, Candiolo, Italy	G. J. Timmers, Amstelveen, the Netherlands
F. Di Raimundo, Catania, Italy	M. J. Kersten, Amsterdam, the Netherlands
R. Centurioni, Civitanova Marche, Italy	A. M. de Kreuk, Amsterdam, the Netherlands
F. Morabito, Cosenza, Italy	S. Zweegman, Amsterdam, the Netherlands
A. Gallamini, Cuneo, Italy	W. E. Terpstra, Amsterdam, the Netherlands
S. Capalbo, Foggia, Italy	C. G. Schaar, Apeldoorn, the Netherlands
R. Mozzana, Gallarate, Italy	E. van der Spek, Arnhem, the Netherlands
S. Aquino, Genova, Italy	L. M. Faber, Beverwijk, the Netherlands
G. Cimino, Latina, Italy	R. S. Boersma, Breda, the Netherlands
P. Ferrando, Lecco, Italy	R. F. J. Schop, Capelle aan den IJssel, the Netherlands
	R. E. Brouwer, Delft, the Netherlands

J. F. M. Pruijt, Den Bosch, the Netherlands	M. E. P. Smeets, Winterswijk, the Netherlands
P. F. Ypma, Den Haag, the Netherlands	K. G. van der Hem, Zaandam, the Netherlands
C. Westerhuis-Siemes, Deventer, the Netherlands	E. Kneppers, Zwolle, the Netherlands
M. D. Levin, Dordrecht, the Netherlands	R. Brudevold, Alesund, Norway
S. Hovenga, Drachten, the Netherlands	D. Szatkowski, Førde, Norway
G. A. Velders, Ede, the Netherlands	N. Gulbrandsen, Oslo, Norway
L. W. Tick, Eindhoven, the Netherlands	F. H. Schjesvold, Sandvika-Baerum, Norway
C. R. van Rooijen, Enschede, the Netherlands	E. Haukås, Stavanger, Norway
A. E. M. Smals, Geldrop, the Netherlands	A. Vik, Tromsø, Norway
Y. Bilgin, Goes, the Netherlands	A. Waage, Trondheim, Norway
M. A. Davidis-Van Schoonhoven, Gorinchem, the Netherlands	S. Carvalho, Lisbon, Portugal
T. H. Levenga, Gouda, the Netherlands	U. H. Mellqvist, Borås, Sweden
W. W. H. Roeloffzen, Groningen, the Netherlands	Y. Hammarlund, Falun, Sweden
P. W. G. van der Linden, Haarlem, the Netherlands	U. H. Mellqvist, Göteborg, Sweden
G. K. S. Jie, Heerlen, the Netherlands	L. Ahlberg, Linköping, Sweden
E. M. G. Jacobs, Helmond, the Netherlands	B. Lauri, Luleå, Sweden
M. H. Silbermann, Hilversum, the Netherlands	M. Hansson, Lund, Sweden
A. Beeker, Hoofddorp, the Netherlands	B. Andreasson, Uddevalla, Sweden
T. M. van Maanen-Lamme, Hoorn, the Netherlands	K. C. Forsberg, Umeå, Sweden
P. A. von dem Borne, Leiden, the Netherlands	M. S. Carlsson, Vaxjö, Sweden
G. M. J. Bos, Maastricht, the Netherlands	B. Uggla, Örebro, Sweden
O. de Weerd, Nieuwegein, the Netherlands	N. Cantoni, Aarau, Switzerland
A. J. Croockewit, Nijmegen, the Netherlands	D. Heim, Basel, Switzerland
C. M. P. W. Mandigers, Nijmegen, the Netherlands	E. Lerch, Bellinzona, Switzerland
M. H. W. van de Poel, Roermond, the Netherlands	T. Pabst, Bern, Switzerland
N. C. H. P. van der Burg-de Graauw, Roosendaal, the Netherlands	U. Mey, Chur, Switzerland
F. Croon-de Boer, Rotterdam, the Netherlands	K. Samii, Geneva, Switzerland
M. B. L. Leys, Rotterdam, the Netherlands	G. Favre, Liestal, Switzerland
P. Sonneveld, Rotterdam, the Netherlands	T. Zander, Luzern, Switzerland
H. C. T. van Zaanen, Rotterdam, the Netherlands	C. Driessen, St Gallen, Switzerland
N. Durdu-Rayman, Schiedam, the Netherlands	D. Rauch, Thun, Switzerland
M. F. Durian, Tilburg, the Netherlands	R. Mueller, Zürich, Switzerland
C. Lensen, Uden, the Netherlands	H. Özdogu, Adana, Turkey
M. C. Minnema, Utrecht, the Netherlands	M. Beksac, Ankara, Turkey
A. Koster, Venlo, the Netherlands	A. Ünal, Kayseri, Turkey




FIG A1. CONSORT diagram of trial patients. The part related to the R2 random assignment has been marked with blue. HSCT, hematopoietic stem-cell transplantation; VMP, bortezomib/melphalan/prednisone; VRD, bortezomib, lenalidomide, and dexamethasone.




FIG A2. Duration of Maintenance. VRD, bortezomib, lenalidomide, and dexamethasone.




FIG A3. OS from R2. D, death; OS, overall survival; VRD, bortezomib, lenalidomide, and dexamethasone.

TABLE A1. Baseline Characteristics at Entry

Characteristic	No Consolidation	Consolidation
Patients, No.	427	451
Age, years, median (IQR)	58 (52-62)	57 (52-62)
Sex, No. (%)		
Male	242 (57)	260 (58)
Female	185 (43)	191 (42)
WHO PS 2 plus 3, No. (%)	56 (13)	62 (14)
ISS stage, No. (%)		
1	180 (42)	189 (42)
2	172 (40)	167 (37)
3	75 (18)	95 (21)
FISH available, No. (%)	379 (89)	402 (89)
del(17p), No. (%)	36/367 (10)	41/386 (11)
t(4;14), No. (%)	41/361 (11)	37/379 (10)
t(14;16), No. (%)	15/335 (4)	12/370 (3)
1qamp1, No. (%)	130/329 (34)	120/356 (30)
Genetic risk available, No. (%)	339 (79)	361 (80)
Standard	256 (76)	276 (76)
High	83 (24)	85 (24)
Revised ISS, No. (%)		
I	83 (19)	112 (25)
II	242 (57)	244 (54)
III	27 (6)	40 (9)
Unknown	75 (18)	55 (12)

Abbreviations: FISH, fluorescent in situ hybridization; IQR, interquartile range; ISS, International Staging System; PS, performance status.

TABLE A2. AEs of CTCAE Grade 3 and 4 During Bortezomib, Lenalidomide, and Dexamethasone

AE	Grade 3, No. (%)	Grade 4, No. (%)
Any	101 (23)	21 (5)
Neutropenia	47 (11)	10 (2)
Thrombocytopenia	43 (10)	9 (2)
General disorders	10 (2)	1 (< 1)
Infections and febrile neutropenia	17 (4)	2 (< 1)
Nervous system disorders	4 (1)	—
Anemia	6 (1)	—
GI and hepatic disorders	3 (1)	—
Metabolic	10 (2)	—
Skin and subcutaneous disorders	1 (< 1)	2 (< 1)
Respiratory, thoracic, and mediastinal disorders	4 (1)	1 (< 1)
Vascular	3 (1)	—
Cardiac	1 (< 1)	—

Abbreviation: AE, adverse event.

TABLE A3. International Uniform Response Criteria Consensus Recommendations¹¹

Response	Definition
sCR	CR as defined below, plus Normal free light-chain ratio, and Absence of clonal plasma cells by immunohistochemistry, immunofluorescence ^a , or two-color to four-color flow cytometry
CR ^b	Negative immunofixation of serum and urine, and Disappearance of any soft tissue plasmacytomas, and < 5% plasma cells in bone marrow
VGPR ^c	Serum and urine M-component detectable by immunofixation but not on electrophoresis, or ≥ 90% reduction in serum M-protein plus urine M-protein < 100 mg/24 hours
PR	≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg/24 hours If the serum and urine M-protein are not measurable, a decrease of ≥ 50% in the difference between involved and uninvolved free light-chain levels is required in place of the M-protein criteria If serum and urine M-protein are not measurable and serum free light-chain assay is also not measurable, ≥ 50% reduction in bone marrow plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥ 30% In addition to the above criteria, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required
SD	Not meeting criteria for CR, VGPR, PR, or PD
PD	Increase of 25% from lowest response value in any one of the following: Serum M-component (absolute increase must be ≥ 0.5 g/dL) Urine M-component (absolute increase must be ≥ 200 mg/24 hours) Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light-chain levels (absolute increase must be > 10 mg/dL) Only in patients without measurable serum and urine M-protein levels and without measurable disease by free light-chain levels: bone marrow plasma cell percentage (absolute percentage must be > 10%) Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder

NOTE. All response categories (sCR, CR, VGPR, PR, and PD) require two consecutive assessments made at any time before the institution of any new therapy; CR, sCR, VGPR, PR, and SD categories also require no known evidence of progressive or new bone lesions if radiographic studies were performed. VGPR and CR categories require serum and urine studies regardless of whether disease at baseline was measurable on serum, urine, both, or neither. Radiographic studies are not required to satisfy these response requirements. Bone marrow assessments need not be confirmed. For PD, serum M-component increases of ≥ 1 g/dL are sufficient to define relapse if starting M-component is ≥ 5 g/dL.

Abbreviations: CR, complete response; IMWG, International Myeloma Working Group; PD, disease progression; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.

^aPresence or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is a kappa/lambda ratio of > 4:1 or < 1:2.

^bClarifications to IMWG criteria for coding CR and VGPR in subjects in whom the only measurable disease is by serum free light-chain levels: CR in such subjects indicates a normal free light-chain ratio of 0.26-1.65 in addition to the CR criteria listed above. VGPR in such subjects requires a > 90% decrease in the difference between involved and uninvolved free light-chain levels.

^cClarifications to IMWG criteria for coding PD: bone marrow criteria for PD are to be used only in subjects without measurable disease by M-protein and by free light-chain levels; 25% increase refers to M-protein, free light-chain, and bone marrow results, and does not refer to bone lesions, soft tissue plasmacytomas, or hypercalcemia, and the lowest response value does not need to be a confirmed value.